More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$447103360
EPS
-1
P/E ratio
--
Price to sales
2.45
Dividend yield
--
Beta
0.690183
Previous close
$5.88
Today's open
$5.85
Day's range
$5.47 - $5.95
52 week range
$5.02 - $18.31
show more
CEO
Steven basta
Employees
371
Headquarters
Florham Park, NJ
Exchange
Nasdaq Global Select
Shares outstanding
81291520
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Phathom: 3 Key Takeaways for Long-Term Investors
Phathom reported third-quarter net revenues of $84.7 million. Commercially insured patients can access VOQUEZNA for a $0 copay through BlinkRx.
The Motley Fool • 6 hours ago

Implied Volatility Surging for Phathom Pharmaceuticals Stock Options
Investors need to pay close attention to PHAT stock based on the movements in the options market lately.
Zacks Investment Research • Nov 6, 2026

Phathom Pharmaceuticals to Participate in November Investor Conferences
FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA Date: Tuesday, November 10, 2026Fireside Chat: 3:00 p.m.
GlobeNewsWire • Nov 4, 2026

Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
A Media Snippet accompanying this announcement is available by clicking on this link.
GlobeNewsWire • Nov 3, 2026

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
Phathom Pharmaceuticals NASDAQ: PHAT reported third-quarter 2026 revenue growth and a second consecutive quarter of positive operating profit excluding stock-based compensation, as the company continued efforts to expand access to its GERD treatment VOQUEZNA.
MarketBeat • Oct 29, 2026

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 29, 2026

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Over 2 million total VOQUEZNA® prescriptions filled through October 16, 2026 Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs.
GlobeNewsWire • Oct 29, 2026

Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.15 per share a year ago.
Zacks Investment Research • Oct 29, 2026

Phathom Pharmaceuticals Provides Update on FDA Litigation
FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced the U.S. Food and Drug Administration's (FDA's) establishment of a public docket (Docket No. FDA-2026-N-13038) to solicit comment on legal and regulatory questions regarding certain issues raised by a filer of an abbreviated new drug application (ANDA) referencing VOQUEZNA® (vonoprazan) tablets, BDR Pharmaceuticals, International Pvt. Ltd. (BDR), in litigation brought against the FDA following FDA's rejection of the ANDA. The litigation was brought to challenge FDA's June 6, 2025 decision granting Phathom's Citizen Petition, which agreed with Phathom that VOQUEZNA benefits from 10 years of New Chemical Entity (NCE) exclusivity through May 3, 2032. The deadline for comments submitted to the public docket is November 23, 2026.
GlobeNewsWire • Oct 26, 2026

Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that BDR Pharmaceuticals International Pvt. Ltd. (BDR) has filed suit against the U.S. Food and Drug Administration (FDA) and related Federal Defendants in the United States District Court for the District of Columbia, principally challenging FDA's alleged refusal to receive an abbreviated new drug application (ANDA) referencing Phathom's new drug application (NDA) for VOQUEZNA®. In the suit, BDR alleges that FDA has improperly applied the GAIN Act to extend Phathom's New Chemical Entity (NCE) exclusivity for VOQUEZNA (vonoprazan fumarate) tablets. Phathom is evaluating the BDR filings, but believes that FDA carefully and correctly evaluated this issue in its June 6, 2025 grant of Phathom's December 11, 2024 Citizen Petition, in which FDA recognized 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032. Phathom intends to take appropriate action to protect its statutory exclusivities.
GlobeNewsWire • Oct 23, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Phathom Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.